Masahiko Mori
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study.
Journal: Clinical and experimental rheumatology
Published: April 14, 2025
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
Journal: Annals of the rheumatic diseases
Published: July 01, 2024
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.
Journal: The Lancet. Rheumatology
Published: December 05, 2022
In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan.
Journal: Microbiology spectrum
Published: April 13, 2022
Proposal of Standard for Medical Science Liaison (MSL) Profession in Japan: A Viewpoint from the Japanese Association of Pharmaceutical Medicine (JAPhMed).
Journal: Pharmaceutical medicine
Published: October 08, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Journal: Journal of clinical pharmacology
Published: August 03, 2018
Showing 1-6 of 6
Last Updated: 09/26/2026